Lantern Pharma Inc. (LTRN): History, Ownership, Mission, How It Works & Makes Money

In an era where targeted cancer therapies are revolutionizing treatment, how does Lantern Pharma Inc. (LTRN), a clinical-stage biopharmaceutical company, stand out? Lantern Pharma is headquartered in Dallas, Texas and traded on the NASDAQ under the ticker LTRN, is focused on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. With a market cap of $38.07 million as of April 2025 and an innovative AI platform called RADR®, Lantern Pharma aims to transform the cost, pace, and timeline of oncology drug discovery and development, but how exactly does it work and generate revenue?

Lantern Pharma Inc. (LTRN) History

Lantern Pharma Inc.'s Founding Timeline

Year established

Lantern Pharma Inc. was established in 2009.

Original location

The company was originally located in Dallas, Texas.

Founding team members

The founding team members included:

• Dr. Arun Asaari
• Ramu Potarazu

Initial capital/funding

Lantern Pharma Inc. secured $3 million in seed funding from various sources, including angel investors, grants, and family offices.

Lantern Pharma Inc.'s Evolution Milestones

Lantern Pharma Inc.'s Transformative Moments

• Acquisition of RADR Technology (2012): This was a transformative moment as it set the stage for Lantern Pharma's personalized medicine approach. RADR (Response Algorithm for Drug positioning) uses machine learning to analyze genomic data and predict drug response, which is central to their business model.
• Integration of AI and Machine Learning (2015): Embracing AI and machine learning technologies allowed Lantern Pharma to accelerate drug discovery, optimize clinical trials, and personalize treatments more effectively.
• Initial Public Offering (IPO) in 2020: Going public provided Lantern Pharma with substantial capital to further its research and development efforts, expand its pipeline, and increase its visibility in the market. The company offered 2.8 million shares of common stock at a public offering price of $15.00 per share, resulting in gross proceeds of $42 million.
• Strategic Collaborations and Partnerships: Forming partnerships with other pharmaceutical companies, research institutions, and technology providers has expanded Lantern Pharma's capabilities and access to resources, driving innovation and growth.

To gain more insights into the company's financial standing, consider reading: Breaking Down Lantern Pharma Inc. (LTRN) Financial Health: Key Insights for Investors

Lantern Pharma Inc. (LTRN) Ownership Structure

Lantern Pharma Inc. operates with a mixed ownership structure, featuring a combination of institutional, insider, and retail investors who collectively influence the company’s strategic direction and governance.

Lantern Pharma Inc.'s Current Status

Lantern Pharma Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol LTRN. This status allows it to raise capital through public offerings and subjects it to regulatory oversight, ensuring transparency and accountability to its shareholders.

Lantern Pharma Inc.'s Ownership Breakdown

Understanding the ownership structure of Lantern Pharma provides insights into who has the most significant influence on the company. Here’s a breakdown of the ownership as of April 2025, based on the latest available data:

For more detailed insights into Lantern Pharma's investor profile, you might find this resource helpful: Exploring Lantern Pharma Inc. (LTRN) Investor Profile: Who’s Buying and Why?

Lantern Pharma Inc.'s Leadership

The leadership team at Lantern Pharma is composed of experienced individuals who guide the company's strategic initiatives and operational execution. Key members include:

• Panna Sharma: President and Chief Executive Officer
• Kimball Hall: Chief Financial Officer
• Dr. Arkadiusz Oleschuck: Chief Scientific Officer

These individuals, along with other members of the executive team and board of directors, bring a wealth of experience in pharmaceuticals, biotechnology, and finance to drive Lantern Pharma's mission forward.

Lantern Pharma Inc. (LTRN) Mission and Values

Lantern Pharma is dedicated to revolutionizing cancer treatment through the use of artificial intelligence (AI) and machine learning. Their mission is rooted in developing targeted therapies, reducing drug development costs, and improving patient outcomes.

Lantern Pharma's Core Purpose

Official mission statement

To save time, money, and lives by revolutionizing the development of targeted and effective cancer therapies using our proprietary AI platform, RADR^®, and a data-driven approach.

• Leveraging AI to accelerate drug discovery and development.
• Focusing on targeted therapies to enhance effectiveness and reduce side effects.
• Committing to a data-driven approach to improve decision-making in cancer treatment.

Vision statement

To transform cancer therapy by:

• Pioneering the use of AI and machine learning in drug development.
• Creating a pipeline of innovative and targeted cancer therapies.
• Improving patient outcomes and quality of life through precision medicine.

Company slogan/tagline

Unlocking the promise of precision oncology through AI.

• Emphasizing the role of AI in making cancer treatment more precise.
• Highlighting the commitment to personalized medicine.
• Signifying the potential to transform cancer care through innovative technology.

For more detailed information, you can visit: Mission Statement, Vision, & Core Values of Lantern Pharma Inc. (LTRN).

Lantern Pharma Inc. (LTRN) How It Works

Lantern Pharma Inc. operates as an artificial intelligence (AI)-driven clinical-stage biopharmaceutical company, leveraging its proprietary AI platform, RADR®, to accelerate the development of targeted cancer therapies. By analyzing vast amounts of genomic and clinical data, Lantern Pharma identifies patients most likely to respond to specific drugs, aiming to reduce the time and cost associated with traditional drug development.

Lantern Pharma's Product/Service Portfolio

Lantern Pharma's Operational Framework

Lantern Pharma's operations are centered around its RADR® AI platform, which drives the selection, development, and clinical advancement of its drug candidates. The company's operational framework involves several key steps:

• Data Acquisition and Integration: Gathering and integrating extensive genomic, transcriptomic, and clinical data from various sources.
• AI-Driven Analysis: Utilizing the RADR® platform to analyze data, predict drug response, and identify potential biomarkers.
• Drug Candidate Selection: Selecting and prioritizing drug candidates based on RADR®'s predictions and insights.
• Preclinical and Clinical Development: Conducting preclinical studies to assess safety and efficacy, followed by clinical trials to evaluate the drug's performance in humans.
• Partnerships and Collaborations: Collaborating with research institutions, pharmaceutical companies, and other stakeholders to accelerate drug development and expand the reach of its platform.

Lantern Pharma's Strategic Advantages

Lantern Pharma's strategic advantages stem from its AI-driven approach and focus on targeted cancer therapies:

• Proprietary AI Platform: RADR® provides a unique competitive edge by enabling more informed drug development decisions, potentially reducing costs and timelines.
• Targeted Therapies: Focus on developing therapies for specific patient populations, increasing the likelihood of clinical success and market adoption.
• Experienced Management Team: A team with expertise in AI, drug development, and oncology, guiding the company's strategic direction.
• Strategic Collaborations: Partnerships with leading research institutions and pharmaceutical companies, expanding the company's capabilities and resources.
• Intellectual Property: A growing portfolio of patents and intellectual property protecting its AI platform and drug candidates.

To gain more insights into the financial aspects, consider exploring this resource: Breaking Down Lantern Pharma Inc. (LTRN) Financial Health: Key Insights for Investors

Lantern Pharma Inc. (LTRN) How It Makes Money

Lantern Pharma operates as a clinical-stage biopharmaceutical company that leverages its proprietary artificial intelligence (AI) platform, RADR®, to discover and develop targeted cancer therapies. The company primarily generates revenue through strategic collaborations and partnerships with other pharmaceutical companies, as well as through government grants and contracts related to its research and development activities.

Lantern Pharma's Revenue Breakdown

As a clinical-stage company, Lantern Pharma's revenue streams are primarily composed of collaborative agreements, licensing, and government funding. Here’s a picture of how these revenue streams contribute to the total revenue:

Lantern Pharma's Business Economics

Lantern Pharma's business economics are centered on the strategic use of its RADR® AI platform to enhance drug development and reduce costs. Key aspects include:

• AI-Driven Efficiency: RADR® enables the company to identify and develop promising drug candidates more efficiently than traditional methods, potentially reducing development timelines and costs.
• Precision Medicine Approach: By focusing on targeted therapies, Lantern Pharma aims to increase the likelihood of clinical success and achieve higher market penetration.
• Strategic Partnerships: Collaborations and licensing agreements provide upfront payments, milestone payments, and royalties, which support ongoing research and development.
• Cost Management: The company focuses on maintaining a lean operational structure, prioritizing key research programs, and carefully managing expenses to extend its cash runway.

Lantern Pharma's Financial Performance

Lantern Pharma's financial performance reflects its status as a clinical-stage biopharmaceutical company with a focus on long-term growth. Here are some key points:

• Cash Position: As of the end of 2024, Lantern Pharma reported having approximately $20.7 million in cash and cash equivalents. This strong cash position supports ongoing clinical trials and research activities.
• R&D Expenses: Research and development expenses for 2024 were approximately $9.8 million, reflecting the company's commitment to advancing its drug pipeline.
• Net Loss: Lantern Pharma reported a net loss of approximately $12.4 million for 2024, which is typical for biotech companies in the clinical stage of development.
• Revenue: Total revenue for 2024 was $1.5 million, primarily from collaborative agreements and government grants.

To gain more insights into the values and principles guiding their work, check out Mission Statement, Vision, & Core Values of Lantern Pharma Inc. (LTRN).

Lantern Pharma Inc. (LTRN) Market Position & Future Outlook

Lantern Pharma is focusing on leveraging its AI platform, RADR®, to advance targeted oncology therapies, positioning itself for growth in the precision medicine market. The company's future outlook depends on successful clinical trials, strategic partnerships, and effective commercialization of its drug candidates.

Competitive Landscape

Opportunities & Challenges

Industry Position

Lantern Pharma operates within the competitive oncology therapeutics market. Key aspects of its industry position include:

• Niche Focus: Targeting specific cancer subtypes with personalized therapies.
• Technology Advantage: Utilizing AI and machine learning to enhance drug discovery and development.
• Early Stage: Being an emerging player, the company's success is tied to clinical advancements and market acceptance of its AI-driven approach.

For insights into Lantern Pharma's financial health, see: Breaking Down Lantern Pharma Inc. (LTRN) Financial Health: Key Insights for Investors